Chronic P7C3 treatment restores hippocampal neurogenesis

Sarah E. Latchney, Thomas C. Jaramillo, Phillip D. Rivera, Amelia J. Eisch, Craig M. Powell

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Down syndrome (DS) is the most common genetic cause of intellectual disability and developmental delay. In addition to cognitive dysfunction, DS patients are marked by diminished neurogenesis, a neuropathological feature also found in the Ts65Dn mouse model of DS. Interestingly, manipulations that enhance neurogenesis - like environmental enrichment or pharmacological agents - improve cognition in Ts65Dn mice. P7C3 is a proneurogenic compound that enhances hippocampal neurogenesis, cell survival, and promotes cognition in aged animals. However, this compound has not been tested in the Ts65Dn mouse model of DS. We hypothesized that P7C3 treatment would reverse or ameliorate the neurogenic deficits in Ts65Dn mice. To test this, adult Ts65Dn and age-matched wild-type (WT) mice were administered vehicle or P7C3 twice daily for 3 months. After 3 months, brains were examined for indices of neurogenesis, including quantification of Ki67, DCX, activated caspase-3 (AC3), and surviving BrdU-immunoreactive(+) cells in the granule cell layer (GCL) of the hippocampal dentate gyrus. P7C3 had no effect on total Ki67+, DCX+, AC3+, or surviving BrdU+ cells in WT mice relative to vehicle. GCL volume was also not changed. In keeping with our hypothesis, however, P7C3-treated Ts65Dn mice had a significant increase in total Ki67+, DCX+, and surviving BrdU+ cells relative to vehicle. P7C3 treatment also decreased AC3+ cell number but had no effect on total GCL volume in Ts65Dn mice. Our findings show 3 months of P7C3 is sufficient to restore the neurogenic deficits observed in the Ts65Dn mouse model of DS.

Original languageEnglish (US)
Pages (from-to)86-92
Number of pages7
JournalNeuroscience Letters
Volume591
DOIs
StatePublished - Mar 1 2015

Fingerprint

Neurogenesis
Down Syndrome
Bromodeoxyuridine
Caspase 3
Therapeutics
Cell Size
Cognition
Parahippocampal Gyrus
Dentate Gyrus
Intellectual Disability
Cell Survival
Cell Count
Pharmacology
Brain

Keywords

  • AC3
  • BrdU
  • Dentate gyrus
  • Doublecortin
  • Ki67
  • Neuronal survival

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Chronic P7C3 treatment restores hippocampal neurogenesis. / Latchney, Sarah E.; Jaramillo, Thomas C.; Rivera, Phillip D.; Eisch, Amelia J.; Powell, Craig M.

In: Neuroscience Letters, Vol. 591, 01.03.2015, p. 86-92.

Research output: Contribution to journalArticle

Latchney, Sarah E. ; Jaramillo, Thomas C. ; Rivera, Phillip D. ; Eisch, Amelia J. ; Powell, Craig M. / Chronic P7C3 treatment restores hippocampal neurogenesis. In: Neuroscience Letters. 2015 ; Vol. 591. pp. 86-92.
@article{3b7daf654ae7412c92c3058345ee0b52,
title = "Chronic P7C3 treatment restores hippocampal neurogenesis",
abstract = "Down syndrome (DS) is the most common genetic cause of intellectual disability and developmental delay. In addition to cognitive dysfunction, DS patients are marked by diminished neurogenesis, a neuropathological feature also found in the Ts65Dn mouse model of DS. Interestingly, manipulations that enhance neurogenesis - like environmental enrichment or pharmacological agents - improve cognition in Ts65Dn mice. P7C3 is a proneurogenic compound that enhances hippocampal neurogenesis, cell survival, and promotes cognition in aged animals. However, this compound has not been tested in the Ts65Dn mouse model of DS. We hypothesized that P7C3 treatment would reverse or ameliorate the neurogenic deficits in Ts65Dn mice. To test this, adult Ts65Dn and age-matched wild-type (WT) mice were administered vehicle or P7C3 twice daily for 3 months. After 3 months, brains were examined for indices of neurogenesis, including quantification of Ki67, DCX, activated caspase-3 (AC3), and surviving BrdU-immunoreactive(+) cells in the granule cell layer (GCL) of the hippocampal dentate gyrus. P7C3 had no effect on total Ki67+, DCX+, AC3+, or surviving BrdU+ cells in WT mice relative to vehicle. GCL volume was also not changed. In keeping with our hypothesis, however, P7C3-treated Ts65Dn mice had a significant increase in total Ki67+, DCX+, and surviving BrdU+ cells relative to vehicle. P7C3 treatment also decreased AC3+ cell number but had no effect on total GCL volume in Ts65Dn mice. Our findings show 3 months of P7C3 is sufficient to restore the neurogenic deficits observed in the Ts65Dn mouse model of DS.",
keywords = "AC3, BrdU, Dentate gyrus, Doublecortin, Ki67, Neuronal survival",
author = "Latchney, {Sarah E.} and Jaramillo, {Thomas C.} and Rivera, {Phillip D.} and Eisch, {Amelia J.} and Powell, {Craig M.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.neulet.2015.02.008",
language = "English (US)",
volume = "591",
pages = "86--92",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Chronic P7C3 treatment restores hippocampal neurogenesis

AU - Latchney, Sarah E.

AU - Jaramillo, Thomas C.

AU - Rivera, Phillip D.

AU - Eisch, Amelia J.

AU - Powell, Craig M.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Down syndrome (DS) is the most common genetic cause of intellectual disability and developmental delay. In addition to cognitive dysfunction, DS patients are marked by diminished neurogenesis, a neuropathological feature also found in the Ts65Dn mouse model of DS. Interestingly, manipulations that enhance neurogenesis - like environmental enrichment or pharmacological agents - improve cognition in Ts65Dn mice. P7C3 is a proneurogenic compound that enhances hippocampal neurogenesis, cell survival, and promotes cognition in aged animals. However, this compound has not been tested in the Ts65Dn mouse model of DS. We hypothesized that P7C3 treatment would reverse or ameliorate the neurogenic deficits in Ts65Dn mice. To test this, adult Ts65Dn and age-matched wild-type (WT) mice were administered vehicle or P7C3 twice daily for 3 months. After 3 months, brains were examined for indices of neurogenesis, including quantification of Ki67, DCX, activated caspase-3 (AC3), and surviving BrdU-immunoreactive(+) cells in the granule cell layer (GCL) of the hippocampal dentate gyrus. P7C3 had no effect on total Ki67+, DCX+, AC3+, or surviving BrdU+ cells in WT mice relative to vehicle. GCL volume was also not changed. In keeping with our hypothesis, however, P7C3-treated Ts65Dn mice had a significant increase in total Ki67+, DCX+, and surviving BrdU+ cells relative to vehicle. P7C3 treatment also decreased AC3+ cell number but had no effect on total GCL volume in Ts65Dn mice. Our findings show 3 months of P7C3 is sufficient to restore the neurogenic deficits observed in the Ts65Dn mouse model of DS.

AB - Down syndrome (DS) is the most common genetic cause of intellectual disability and developmental delay. In addition to cognitive dysfunction, DS patients are marked by diminished neurogenesis, a neuropathological feature also found in the Ts65Dn mouse model of DS. Interestingly, manipulations that enhance neurogenesis - like environmental enrichment or pharmacological agents - improve cognition in Ts65Dn mice. P7C3 is a proneurogenic compound that enhances hippocampal neurogenesis, cell survival, and promotes cognition in aged animals. However, this compound has not been tested in the Ts65Dn mouse model of DS. We hypothesized that P7C3 treatment would reverse or ameliorate the neurogenic deficits in Ts65Dn mice. To test this, adult Ts65Dn and age-matched wild-type (WT) mice were administered vehicle or P7C3 twice daily for 3 months. After 3 months, brains were examined for indices of neurogenesis, including quantification of Ki67, DCX, activated caspase-3 (AC3), and surviving BrdU-immunoreactive(+) cells in the granule cell layer (GCL) of the hippocampal dentate gyrus. P7C3 had no effect on total Ki67+, DCX+, AC3+, or surviving BrdU+ cells in WT mice relative to vehicle. GCL volume was also not changed. In keeping with our hypothesis, however, P7C3-treated Ts65Dn mice had a significant increase in total Ki67+, DCX+, and surviving BrdU+ cells relative to vehicle. P7C3 treatment also decreased AC3+ cell number but had no effect on total GCL volume in Ts65Dn mice. Our findings show 3 months of P7C3 is sufficient to restore the neurogenic deficits observed in the Ts65Dn mouse model of DS.

KW - AC3

KW - BrdU

KW - Dentate gyrus

KW - Doublecortin

KW - Ki67

KW - Neuronal survival

UR - http://www.scopus.com/inward/record.url?scp=84923013532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923013532&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2015.02.008

DO - 10.1016/j.neulet.2015.02.008

M3 - Article

VL - 591

SP - 86

EP - 92

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

ER -